Neurologists’ perspectives of cannabis-based medicines: results from an all-Ireland survey
Abstract Background: Advancements continue to be made in the development of medicines containing components of the Cannabis sativa L. plant.…
Eric J. Downer
Botanically-Derived Δ9-Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis
Abstract The innate immune response to bacterial and viral molecules involves the coordinated production of cytokines, chemokines, and type I…
Cannabidiol modulation of oxidative stress and signalling
Abstract Cannabidiol (CBD), one of the primary non-euphoric components in the Cannabis sativa L. plant, has undergone clinical development over…
Phytocannabinoid‐dependent mTORC1 regulation is dependent upon inositol polyphosphate multikinase activity
Abstract Background and Purpose: Cannabidiol (CBD) has been shown to differentially regulate the mechanistic target of rapamycin complex 1 (mTORC1)…